FDA Advocacy
Learn about our work to bring the voice of people concerned about women’s health to decision-makers who create and implement health policies.
Featured Posts
Sorry, we couldn't find any content.
Browse our FDA ADVOCACY work:
Results for:
An Open Letter to FDA’s New Commissioner
By: Cindy Pearson ,FDA Advocacy, FDA Commissioner Deep Dive ArticlesThe public pays for more than half of the FDA's budget each year, which entitles us to have a say in the agency’s operations. Late last year, we gave your predecessor, Scott Gottlieb, a report card on his first year...
The NWHN’s Statement on the FDA Ordering Manufacturers of Surgical Mesh to Stop Selling Devices for Uterine Prolapse
By: Cindy Pearson ,FDA Advocacy, Gynecological Health, Pelvic Organ Prolapse, Surgical Mesh, Transvaginal Mesh Press ReleasesFOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240
FDA General and Plastic Surgery Devices Panel Meeting on Breast Implant Safety
By: Tessa Ruff ,Breast Health, Breast Implants, FDA Advocacy Deep Dive ArticlesEarlier in March, the FDA sent warning letters to two breast implant manufacturers, Mentor and Sientra, citing their failure to conduct safety studies after approval. In Australia and France, authorities have been pulling textured implants off the market due to...
The NWHN’s Statement on the FDA Ordering Sprout Pharmaceuticals to Retain Black Box Label Warning Women Not Mix Addyi and Alcohol
By: Cindy Pearson ,Addyi, FDA Advocacy, Flibanserin, Sex Drugs for Women Press ReleasesFOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240
NWHN Statement in Response to the FDA’s Action Against Aid Access
By: Cindy Pearson ,Abortion, FDA Advocacy, Medication Abortion, Mifepristone Press ReleasesFOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240
The NWHN’s Statement on the Resignation of FDA Commissioner Scott Gottlieb
By: Cindy Pearson ,FDA Advocacy, FDA Commissioner, Scott Gottlieb Press ReleasesFOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240
The NWHN Testifies for the Use of Better Evidence at the FDA
By: Tessa Ruff ,FDA Advocacy, Gynecological Health, Transvaginal Mesh, Vaginal Mesh Policy UpdatesIn 2016, the FDA reclassified transvaginal mesh used to repair pelvic organ prolapse (POP) as a Class III device—the highest risk category—in response to over 20,000 adverse event reports during a three-year period alone.
Taking on Gender Bias in Clinical Trials
By: Caitlin Hoff ,Clinical Trials, FDA Advocacy Deep Dive ArticlesWe have made progress as a country, but there is still work to be done. Clinical trials need to broaden their subject base and do a better job of representing all affected parties for the sake of equality and the...
FDA Meeting – Surgical Mesh for Transvaginal Repair of Pelvic Organ Prolapse
By: Cindy Pearson ,FDA Advocacy, Gynecological Health, Pelvic Organ Prolapse, Surgical Mesh, Transvaginal Mesh TestimonyTestimony Delivered at the Meeting of the FDA Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee
NWHN Statement on FDA’s Decision on Generic Drug Labels
By: Cindy Pearson ,FDA Advocacy, Generic Drug Labeling, Generic Drugs Press ReleasesFOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240